Trial · NCT03844945

Efficacy and Systemic Safety of Netarsudil 0.01%, 0.02%, 0.04% Relative to Placebo in Subjects With Open-angle Glaucoma or Ocular Hypertension in Japan

NCT03844945, Phase 2, Completed, Aerie Pharmaceuticals; results first posted 2020-10-19

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Efficacy and Systemic Safety of Netarsudil 0.01%, 0.02%, 0.04% Relative to Placebo in Subjects With Open-angle Glaucoma or Ocular Hypertension in Japan. Trials, record NCT03844945. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03844945

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Efficacy and Systemic Safety of Netarsudil 0.01%, 0.02%, 0.04% Relative to Placebo in Subjects With Open-angle Glaucoma or Ocular Hypertension in Japan
NCT number: NCT03844945
Status: Completed
Phases: Phase 2
Enrollment: 215 participants, actual
Lead sponsor: Aerie Pharmaceuticals
Conditions: Open Angle Glaucoma, Ocular Hypertension
Interventions: Netarsudil Ophthalmic Solution 0.01%, Netarsudil Ophthalmic Solution 0.02%, Netarsudil Ophthalmic Solution 0.04%, Netarsudil Ophthalmic Solution Placebo
First posted: 2019-02-19
Last updated: 2020-10-19
Results first posted: 2020-10-19

Source ClinicalTrials.gov

Registered outcomes1

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Intraocular Pressure (IOP)	29 Days	Mean diurnal IOP within a treatment by Goldman Applanation Tonometry

Source ClinicalTrials.gov

Outcomes1

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Intraocular Pressure (IOP)	29 Days	Intent to treat (ITT) population	mmHg	MEAN

Source ClinicalTrials.gov

Results by group16

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Intraocular Pressure (IOP)	Netarsudil Ophthalmic Solution 0.01%	Day 1	20.5	Standard Deviation 2.8362	mmHg
Intraocular Pressure (IOP)	Netarsudil Ophthalmic Solution 0.02%	Day 1	20.3	Standard Deviation 2.8039	mmHg
Intraocular Pressure (IOP)	Netarsudil Ophthalmic Solution 0.04%	Day 1	20.8	Standard Deviation 3.2037	mmHg
Intraocular Pressure (IOP)	Netarsudil Ophthalmic Solution Placebo	Day 1	21.1	Standard Deviation 3.7023	mmHg
Intraocular Pressure (IOP)	Netarsudil Ophthalmic Solution 0.01%	Day 8	16.2	Standard Deviation 2.568	mmHg
Intraocular Pressure (IOP)	Netarsudil Ophthalmic Solution 0.02%	Day 8	15.9	Standard Deviation 2.673	mmHg
Intraocular Pressure (IOP)	Netarsudil Ophthalmic Solution 0.04%	Day 8	15.7	Standard Deviation 4.014	mmHg
Intraocular Pressure (IOP)	Netarsudil Ophthalmic Solution Placebo	Day 8	19.8	Standard Deviation 4.059	mmHg
Intraocular Pressure (IOP)	Netarsudil Ophthalmic Solution 0.01%	Day 15	15.9	Standard Deviation 2.703	mmHg
Intraocular Pressure (IOP)	Netarsudil Ophthalmic Solution 0.02%	Day 15	15.6	Standard Deviation 2.573	mmHg

1 to 10 of 16Source ClinicalTrials.gov

See all 16 results by group

Participant flow12

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Netarsudil Ophthalmic Solution 0.01%	55
Overall Study	STARTED	Netarsudil Ophthalmic Solution 0.02%	54
Overall Study	STARTED	Netarsudil Ophthalmic Solution 0.04%	51
Overall Study	STARTED	Netarsudil Ophthalmic Solution Placebo	55
Overall Study	COMPLETED	Netarsudil Ophthalmic Solution 0.01%	54
Overall Study	COMPLETED	Netarsudil Ophthalmic Solution 0.02%	53
Overall Study	COMPLETED	Netarsudil Ophthalmic Solution 0.04%	46
Overall Study	COMPLETED	Netarsudil Ophthalmic Solution Placebo	54
Overall Study	NOT COMPLETED	Netarsudil Ophthalmic Solution 0.01%	1
Overall Study	NOT COMPLETED	Netarsudil Ophthalmic Solution 0.02%	1

1 to 10 of 12Source ClinicalTrials.gov

See all 12 participant flow

Adverse events168

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Conjunctival Hyperemia	Eye disorders	Netarsudil Ophthalmic Solution 0.01%	13	55
other	Conjunctival Hyperemia	Eye disorders	Netarsudil Ophthalmic Solution 0.02%	20	54
other	Conjunctival Hyperemia	Eye disorders	Netarsudil Ophthalmic Solution 0.04%	29	51
other	Conjunctival Hyperemia	Eye disorders	Netarsudil Ophthalmic Solution Placebo	1	55
other	Eye Irritation	Eye disorders	Netarsudil Ophthalmic Solution 0.01%	3	55
other	Eye Irritation	Eye disorders	Netarsudil Ophthalmic Solution 0.02%	5	54
other	Eye Irritation	Eye disorders	Netarsudil Ophthalmic Solution 0.04%	2	51
other	Eye Irritation	Eye disorders	Netarsudil Ophthalmic Solution Placebo	0	55
other	Conjunctival Hemorrhage	Eye disorders	Netarsudil Ophthalmic Solution 0.01%	0	55
other	Conjunctival Hemorrhage	Eye disorders	Netarsudil Ophthalmic Solution 0.02%	3	54

1 to 10 of 168Source ClinicalTrials.gov

See all 168 adverse events

Adverse event totals12

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Netarsudil Ophthalmic Solution 0.01%	0	55
Total, all-cause mortality	Netarsudil Ophthalmic Solution 0.02%	0	54
Total, all-cause mortality	Netarsudil Ophthalmic Solution 0.04%	0	51
Total, all-cause mortality	Netarsudil Ophthalmic Solution Placebo	0	55
Total, other adverse events	Netarsudil Ophthalmic Solution 0.01%	21	55
Total, other adverse events	Netarsudil Ophthalmic Solution 0.02%	27	54
Total, other adverse events	Netarsudil Ophthalmic Solution 0.04%	36	51
Total, other adverse events	Netarsudil Ophthalmic Solution Placebo	5	55
Total, serious adverse events	Netarsudil Ophthalmic Solution 0.01%	0	55
Total, serious adverse events	Netarsudil Ophthalmic Solution 0.02%	0	54

1 to 10 of 12Source ClinicalTrials.gov

See all 12 adverse event totals

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
33629227	DERIVED

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT03844945

GET https://conductscience.org/api/trials/v1/NCT03844945/events?page=2

API reference For AI assistants